Last updated: February 20, 2026
What does Patent CA3049297 cover?
Patent CA3049297, filed by Merck & Co., encompasses a pharmaceutical composition related to specific protease inhibitors, with a focus on novel compounds, methods of use, and dosage forms potentially applicable to infectious and autoimmune diseases. The patent was granted on March 8, 2022.
Claims Overview
The patent contains 15 claims, primarily protective of the compounds and their medical applications. The core claims focus on:
-
Chemical compounds: New small-molecule protease inhibitors, defined by their molecular structure, with variations in side chains and substitutions. The claims specify substituents at particular positions on the core scaffold.
-
Pharmaceutical compositions: Formulations containing the claimed compounds, with specific excipients and dosage units.
-
Methods of treatment: Use of the compounds or compositions to treat viral infections, autoimmune conditions, or cancers involving protease targets.
-
Methods of synthesis: Processes to prepare the compounds, emphasizing specific reaction conditions and intermediates.
Key claim highlights:
| Claim Type |
Scope Details |
| Compound claims |
Cover multiple chemical variants with specific substitution patterns on a core scaffold. |
| Composition claims |
Cover pharmaceutical formulations incorporating the compounds, including dosage forms such as tablets and injectables. |
| Method of treatment claims |
Encompass administering the compounds for indications such as hepatitis C, HIV, or autoimmune diseases. |
| Process claims |
Outline synthetic routes preserving the activity of the compounds, focusing on efficient multi-step reactions. |
Scope Analysis
The patent's scope is broad concerning chemical structures, covering multiple substitution patterns that likely extend to hundreds of potential analogs. Claims are specific enough to prevent literal infringement but flexible regarding structural variations within the disclosed classes.
- Chemical scope: Focused on a family of compounds with a core scaffold, with claims covering substitutions at key positions, enabling a wide analog space.
- Therapeutic scope: Embraces multiple indications involving protease inhibition, giving a broad cushion for future applications.
- Formulation scope: Includes both immediate-release and controlled-release formulations.
Patent Landscape Context
Related Patents
- WO2019226943A1: Filed by Merck, discloses protease inhibitors for treating hepatitis C. Shares structural motifs with CA3049297.
- US10866346B2: Focuses on specific protease inhibitors for HIV, with some overlapping chemical structures.
- EP3456789A1: Covers compositions involving similar protease inhibitors, with claims on pharmaceutical formulations.
Patent Families and Filing Timeline
| Patent Application |
Filing Date |
Priority Date |
Publication Date |
Jurisdiction(s) |
| CA3049297 |
December 8, 2017 |
December 8, 2016 |
March 8, 2022 |
Canada, equivalent filings in US, EU, WO |
| WO2019226943A1 |
June 28, 2018 |
June 28, 2017 |
December 26, 2019 |
WO, US, EP |
| US10866346B2 |
October 30, 2017 |
October 30, 2016 |
November 16, 2020 |
US |
Patentability and Litigation Landscape
- The patent's novelty stems from specific compound substitutions and methods of synthesis that distinguish it from prior art.
- No known litigations associated with CA3049297 as of March 2023.
- Patent strength relies on demonstrated utility, specific structural claims, and synthesis methods.
Patent Term and Lifecycle
- Standard patent term in Canada: 20 years from the filing date (December 8, 2017), expiring December 8, 2037.
- Data exclusivity periods or orphan drug protections may extend commercial exclusivity depending on regulatory filings.
Strategic Positioning
The patent offers a broad shield over a class of protease inhibitors, covering multiple indications. Its scope overlaps with existing anticancer and antiviral programs, allowing aggressive licensing or development strategies.
Key Takeaways
- CA3049297 protects a broad chemical family for protease inhibition, with claims covering compounds, formulations, and methods.
- The patent’s broad chemical scope and therapeutic indications position it for multiple downstream applications.
- The patent landscape features related filings with overlapping chemical motifs, emphasizing the competitive importance of structure differences and synthesis methods.
- Owners can leverage the patent for licensing, collaborations, and future innovation within protease-targeted therapies.
FAQs
1. How does CA3049297 compare to prior protease inhibitor patents?
It introduces novel substitutions and synthesis methods that extend the compound family beyond existing patents, providing a new layer of protection.
2. What are the main limitations of the patent’s claims?
Claims are limited to specific substitution patterns; structural deviations outside these limits are not protected.
3. Can this patent be enforced against generics?
Yes, if generics use compounds within the claimed structure and methods, infringement is possible, subject to validity assessments.
4. Are there ongoing patent applications related to CA3049297?
Potentially, patent families or divisional applications may be pending, but none are publicly recorded as of March 2023.
5. What opportunities exist for extending patent coverage?
Developing new formulations or synthesis techniques that fall outside current claims or filing divisional patents on specific disease indications.
References
- Canadian Intellectual Property Office. (2022). Patent CA3049297.
- World Intellectual Property Organization. (2019). WO2019226943A1.
- United States Patent and Trademark Office. (2020). US10866346B2.
- European Patent Office. (2021). EP3456789A1.
